NIH-funded research R21 grant

Investigating how immune proteins affect COVID-19 severity

Official title: Intracellular Membrane Attack Complexes and COVID-19 Immune Hyperactivation

Funded at Yale University · NIH-10844646 · Data updated 2026-11-12

This study is looking at how certain proteins in your immune system might cause problems in your blood vessels during severe COVID-19, and it's for anyone interested in understanding why some people get sicker than others.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionYale University
NIH-funded
Lab location1 site (New Haven, United States)
Project startMay 19, 2023
Project endApril 30, 2026
Funding year2024
Award (this year)$209,375
NIH project number5R21AI178582-02
Project IDNIH-10844646 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients experiencing severe COVID-19 symptoms, particularly those showing signs of immune hyperactivation.

Less likely to help

Patients with mild COVID-19 symptoms or those who have recovered from the virus may not benefit from this research.

What this research studies

This research explores the role of complement proteins in the immune response during severe COVID-19. It focuses on how these proteins form membrane attack complexes that can disrupt cell function without causing cell death. By examining the internalization of these complexes in endothelial cells, the study aims to uncover new mechanisms of immune hyperactivation that contribute to tissue injury in COVID-19 patients. The approach includes using specific viral antigens to trigger the formation of these complexes and studying their effects on cell behavior.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies to mitigate immune-related damage in COVID-19 patients.

How similar studies have gone: While the role of complement proteins in immune responses is well-established, this specific investigation into their non-cytolytic effects in COVID-19 is novel and has not been extensively tested.

Where this research is happening

  • Yale University
    New Haven, United States
    Active

Researchers

  • Principal investigator: Jane-Wit, Daniel — Yale University
  • Study coordinator: Jane-Wit, Daniel

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.